Lung Cancer
From the Journals
Pembrolizumab plus chemoradiotherapy shows early promise in NSCLC
Researchers deemed the combination “feasible and well tolerated,” with a “promising” progression-free survival rate at 12 months.
From the Journals
Medicaid expansion linked to more early cancer diagnoses
Patients in states that opted for Medicaid insurance expansion saw an increase in the rate of early diagnoses but similar wait times to treatment...
From the Journals
Tumor neoantigenicity metric improves prediction of response to immunotherapy
A new scoring system can predict response to immunotherapy in patients with melanoma, lung cancer, and kidney cancer.
From the Journals
Glaring gap in CV event reporting in pivotal cancer trials
News
FDA: Cell phones still look safe
The available evidence does not suggest a causal link between cell phone use and cancer, according to the FDA.
Feature
Funding failures: Tobacco prevention and cessation
Most states fall far below minimum spending guidelines, according to American Lung Association.
From the Journals
Uptick in lung cancer in younger women, not related to smoking
Historically, lung cancer rates have been higher in men, but a new study shows higher rates in women.
Applying research to practice
New tools could help predict complication risks in lung and breast cancer
More evidence is needed before clinicians can rely on these new tools.
From the Journals
Global project reveals cancer’s genomic playbook
The Pan-Cancer Analysis of Whole Genomes, an international collaboration, reveals the complexity of oncogenesis.
From the Journals
Walk test may predict complications after lung cancer surgery
Findings suggest role for curative resection in patients with moderately decreased lung function but a longer 6-minute walk distance,...
From the Journals
Lenvatinib/pembrolizumab has good activity in advanced RCC, other solid tumors
Two-thirds of patients with advanced renal cell carcinoma had a clinical response to the TKI/immune checkpoint inhibitor combination.